Inhibrx shares surged over 60% after its cancer drug ozekibart showed a 52% reduction in disease progression, with FDA filing planned for Q2 2026.The post Why Is Inhibrx Biosciences (INBX) Stock Surging in Premarket Today? appeared first on Tokenist.